JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB189173

Anti-TRC8 antibody - C-terminal

Be the first to review this product! Submit a review

|

(1 Publication)

Goat Polyclonal TRC8 antibody. C-terminal. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human RNF139 aa 650 to C-terminus.

View Alternative Names

TRC8, RNF139, E3 ubiquitin-protein ligase RNF139, RING finger protein 139, RING-type E3 ubiquitin transferase RNF139, Translocation in renal carcinoma on chromosome 8 protein

3 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRC8 antibody - C-terminal (AB189173)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRC8 antibody - C-terminal (AB189173)

Immunohistochemistry analysis of Formalin-fixed, paraffin-embedded Human placenta tissue labeling TRC8 with ab189173 at 3.75μg/ml.

Western blot - Anti-TRC8 antibody - C-terminal (AB189173)
  • WB

Supplier Data

Western blot - Anti-TRC8 antibody - C-terminal (AB189173)

TRC8 (1µg/ml) staining of Human Skeletal Muscle lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence  Western blot : Approx 75kDa band observed in Human Skeletal Muscle lysates (calculated MW of 76.0kDa according to NP_009149.2). Recommended concentration : 0.3-1µg/ml.

All lanes:

Western blot - Anti-TRC8 antibody - C-terminal (ab189173)

All lanes:

Human Skeletal Muscle lysate at 35 µg

Predicted band size: 76 kDa

Observed band size: 76 kDa

false

Western blot - Anti-TRC8 antibody - C-terminal (AB189173)
  • WB

Supplier Data

Western blot - Anti-TRC8 antibody - C-terminal (AB189173)

All lanes:

Western blot - Anti-TRC8 antibody - C-terminal (ab189173) at 0.5 µg/mL

All lanes:

Human skeletal muscle cell lysate in RIPA buffer at 35 µg/mL

Predicted band size: 76 kDa

true

Exposure time: 1hr

Key facts

Host species

Goat

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, IHC-P

applications

Immunogen

Synthetic Peptide within Human RNF139 aa 650 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

Q8WU17

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "3.75 µg/mL", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.3-1 µg/mL", "WB-species-notes": "<p></p>" }, "Gorilla": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Monkey": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Orangutan": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rabbit": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.3 Preservative: 0.02% Sodium azide Constituents: 99% Tris buffered saline, 0.5% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRC8 also known as RNF139 or RING finger protein 139 is an E3 ubiquitin ligase that plays a role in protein degradation through ubiquitination. TRC8 has a mass of approximately 88 kDa. It is a transmembrane protein found in the endoplasmic reticulum. The presence of its RING finger domain aids in transferring ubiquitin to substrate proteins marking them for proteasomal degradation. TRC8 is expressed in multiple tissues and cells including the liver and prostate suggesting various functional roles.
Biological function summary

TRC8 is involved in the regulation of protein quality control by mediating the degradation of defective proteins within the endoplasmic reticulum. As part of the complex machinery of the ubiquitin-proteasome system TRC8 oversees protein homeostasis assisting in the removal of misfolded or unnecessary proteins to maintain cellular balance. This function impacts several cellular processes and maintains the health of the cell under stress conditions.

Pathways

The TRC8 protein interacts with components of the endoplasmic reticulum-associated degradation (ERAD) pathway which is a critical process for maintaining protein balance. TRC8 works alongside other proteins like HRD1 and SEL1L in this pathway to ensure the clearance of defective proteins. It also influences the sterol regulatory element-binding protein (SREBP) pathway impacting cholesterol synthesis and homeostasis.

The role of TRC8 is significant in cancer and genetic syndromes. Mutations or deletions in the TRC8 gene associate with hereditary leiomyomatosis and renal cell cancer (HLRCC) where its interaction with proteins like fumarate hydratase is important. It is also implicated in neurodegenerative disorders where dysfunctional ubiquitin ligase activity impacts neuronal protein homeostasis potentially linked through connections with proteins like Parkin in managing protein aggregations.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

E3-ubiquitin ligase; acts as a negative regulator of cell proliferation through mechanisms involving G2/M arrest and cell death (PubMed : 10500182, PubMed : 12032852, PubMed : 17016439). Required for MHC class I ubiquitination in cells expressing the cytomegalovirus protein US2 before dislocation from the endoplasmic reticulum (ER) (PubMed : 19720873). Affects SREBP processing by hindering the SREBP-SCAP complex translocation from the ER to the Golgi, thereby reducing SREBF2 target gene expression (PubMed : 19706601, PubMed : 20068067). Involved in the sterol-accelerated degradation of HMGCR (PubMed : 22143767, PubMed : 23223569). This is achieved through binding of RNF139 to INSIG1 and/or INSIG2 at the ER membrane (PubMed : 22143767). In addition, interaction of RNF139 with AUP1 facilitates interaction of RNF139 with ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase AMFR, leading to ubiquitination of HMGCR (PubMed : 23223569). The ubiquitinated HMGCR is then released from the ER into the cytosol for subsequent destruction (PubMed : 22143767, PubMed : 23223569). Required for INSIG1 ubiquitination (PubMed : 20068067). May be required for EIF3 complex ubiquitination (PubMed : 20068067).
See full target information RNF139
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Journal of experimental & clinical cancer research : CR 42:238 PubMed37697370

2023

Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.

Applications

Unspecified application

Species

Unspecified reactive species

Chunhua She,Chao Wu,Weihua Guo,Yongjie Xie,Shouyi Li,Weishuai Liu,Chao Xu,Hui Li,Pei Cao,Yanfang Yang,Xiuchao Wang,Antao Chang,Yukuan Feng,Jihui Hao
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB191691

Anti-UBIAD1 antibody - C-terminal

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-UBIAD1 antibody - C-terminal (AB191691)

  • 0
  • 0
Primary Antibodies

AB187156

Anti-USP25 antibody [EPR15019]

RabMAb|Recombinant

Flow Cytometry (Intracellular) - Anti-USP25 antibody [EPR15019] (AB187156)

  • 0
  • 0
Secondary Antibodies

AB125912

Rabbit monoclonal [H26-10] Anti-Human IgG1 H&L

RabMAb|Recombinant

ELISA - Rabbit monoclonal [H26-10] Anti-Human IgG1 H&L (AB125912)

  • 0
  • 0
Primary Antibodies

AB317579

Anti-CCXCR1/XCR1 antibody [CIA207A] - BSA and Azide free

BOND RX™ Validated|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CCXCR1/XCR1 antibody [CIA207A] - BSA and Azide free (AB317579)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com